Saxol, newborn company develops innovative compounds able to fight and/or to prevent peripheral neuropathies, including Diabetes peripheral neuropathies, Immuno and Chemotherapy-Induced Peripheral Neuropathies (CIPN). Based on IAB research on Carbazole structure (Lafanechère Team) and with the support of Linksium, we plan to bring to patients, new neuroprotective drugs to answers current Unmet Medical needs
CARBA1, our lead compound has neuroprotective activity through a mechanism of regulation and reactivation of energy production at the cellular level.
We plan first to develop Carba1 for CIPN Unmet Medical Need and to enlarge after to Diabetes Peripheral Neuropathy DPN and other PN
#CIPN # DPN #Pain #Nerve #Neuropathicpain #Chemotherapy #Cancer # Diabetes #Peripheralneuropathy #Burning #Unmetmedicalneed #Immunotherapy
Company Details
- Employees
- 4
- Founded
- -
- Address
- Grenoble - Lyon, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.saxol.eu
- Keywords
- oncology, neuropathies, peripheral neuropathies, chemotherapies, drug development, pharmaceuticals, CIPN, Diabetes, neuroprotection, Small molecule, immunotherapies, neurons.
- HQ
- Grenoble - Lyon
Saxol Questions
Saxol's website is http://www.saxol.eu
Saxol's LinkedIn profile is https://fr.linkedin.com/company/saxol
Saxol has
4 employees.
View email and phone details for 4
employees at Saxol.
Saxol's industry is
Biotechnology Research
Saxol's top competitors are
Lyonbiopôle Auvergne-Rhône-Alpes,
Admentia,
Servatrix Biomed S.l,
Ais Biotech,
Apmonia Therapeutics,
Ervimmune,
Capital Cell,
Nawu Diagnostics,
Pomega Laboratories,
Sirius Neosight.
Saxol's categories are Biotechnology Research
Saxol's founding year is 2024
